Nature of the Business - Additional Information (Detail) - USD ($)		1 Months Ended				3 Months Ended
	Dec. 03, 2019	Mar. 27, 2020	Jul. 25, 2019	Jul. 12, 2019	May 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Apr. 15, 2019	Apr. 03, 2017
Summary Of Significant Accounting Policies [Line Items]
Proceeds from maturities and sales of marketable securities							$ 29,500,000
Proceeds on sale of property and equipment							615,000
Special cash dividend paid	$ 6,700,000		$ 20,000,000
Dividend payable date	Dec. 23, 2019		Sep. 05, 2019
Dividend payable, date of record	Dec. 16, 2019		Aug. 28, 2019
Accumulated deficit						$ 540,360,000		$ 540,609,000
Net income						249,000	(10,458,000)
Cash used in operating activities						1,005,000	$ 13,652,000
Cash, cash equivalents and marketable securities						$ 18,000,000
Silver Creek Pharmaceuticals, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Proceeds from maturities and sales of marketable securities					$ 7,800,000
Silver Creek Pharmaceuticals, Inc. [Member] | Laboratory Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Proceeds on sale of property and equipment					$ 1,400,000
Celator Pharmaceuticals Inc [Member]
Summary Of Significant Accounting Policies [Line Items]
Cash payment received		$ 2,300,000
Reimbursement of expenses		200,000
Transaction expenses		$ 400,000
Loan Agreement [Member] | Hercules Capital Inc [Member] | Term Loan [Member]
Summary Of Significant Accounting Policies [Line Items]
Payoff Amount									$ 16,000,000
After Failure Of First Line Chemotherapy [Member]
Summary Of Significant Accounting Policies [Line Items]
Contingent milestone payment recieved										$ 150,000,000
IpsenSAMember | Asset Sale Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional payments receivable on achievement of certain milestone events										450,000,000
IpsenSAMember | First Line Treatment Of Metastatic Adenocarcinoma Of Pancreas [Member]
Summary Of Significant Accounting Policies [Line Items]
Contingent milestone payment recieved										225,000,000
IpsenSAMember | Additional Indication [Member]
Summary Of Significant Accounting Policies [Line Items]
Contingent milestone payment recieved										$ 75,000,000
IpsenSAMember | Ongoing Multi Part Clinical
Summary Of Significant Accounting Policies [Line Items]
Contingent milestone payment recieved								$ 5,000,000
14ner Sale [Member]
Summary Of Significant Accounting Policies [Line Items]
Upfront cash payment received				$ 3,500,000
14ner Sale [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional payments receivable on achievement of certain milestone events				54,500,000
14ner Sale [Member] | Achievement of the Primary Endpoint in the First Registrational Clinical Study of Either MM-121 or MM-111 [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional payments receivable on achievement of certain milestone events				3,000,000
14ner Sale [Member] | Achievement of Various Regulatory Approval and Reimbursement-Based Milestones in the United States, Europe and Japan [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional payments receivable on achievement of certain milestone events				16,500,000
14ner Sale [Member] | Achievement Various Cumulative Worldwide Net Sales Targets Between $100.0 million and $300.0 million for MM-121 and MM-111 [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional payments receivable on achievement of certain milestone events				35,000,000
Cumulative worldwide net sales target				300,000,000
14ner Sale [Member] | Achievement Various Cumulative Worldwide Net Sales Targets Between $100.0 million and $300.0 million for MM-121 and MM-111 [Member] | Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Cumulative worldwide net sales target				$ 100,000,000